When we share our stories for the betterment of others we grow stronger, taking back the power stolen by shame and fear. Below you can read real-life accounts from our community which we hope motivate you to open up new dialogues and even share your own stories. We’d love to hear from you at [email protected].

community

Community: Shared Stories and Comments

Matthew Reeves, MD, MPH Joins WomanCare Global Team

Posted on September 9, 2010

WomanCare Global is pleased to announce that Matthew Reeves, MD, MPH, has joined WomanCare Globalas Vice President, Medical Affairs.

Dr Reeves is board certified in Obstetrics & Gynecology. He most recently served as a Medical Officer at CONRAD and as an assistant professor of Obstetrics & Gynecology at Eastern Virginia Medical School where his work focused on the early phase clinical trials of contraceptive and HIV prevention products. Dr Reeves received a BA in physica lanthropology from the University of Pennsylvania and a medical degree from Harvard Medical School. He completed a residency in Obstetrics & Gynecology at the University of California, San Francisco (UCSF) in 2003 followed by a Fellowship in Ultrasound at UCSF where he earned a certificate in Advanced Training in Clinical Research. In 2006, Dr Reeves completed the Fellowship in Family Planning & Contraceptive Research and the MPH program at the Universityof Pittsburgh. Dr Reeves was on the faculty at the University of Pittsburgh School of Medicine where he was an attending physician at Magee-Womens Hospital in both the Gynecology and Ultrasound divisions. He has authored and co-authored over 30 peer-reviewed publications. Previously, Dr Reeves conducted research on post-placental and postabortal IUD insertion, contraceptive cost-effectiveness, provision of family planning services in the developing world,and applications of ultrasound in family planning. He has worked in Nigeria, Japan, Malawi, Vietnam, Haiti and Guyana.In addition to his role at WomanCare Global, Dr Reeves also serves as a research mentor for the Fellowship in Family Planning & Contraceptive Research at Washington Hospital Center.

About WomanCare Global

WomanCare Global provides access to high-quality, innovative and affordable reproductive health technologies forcontraception, fertility and pregnancy management. WomanCare Global’s mission is to expand the availability of thesetechnologies in both public and private sectors via an established global supply chain reaching over 80 countries andgrowing, with particular focus on under-served markets in Africa, Asia and Latin America. WomanCare Global is a hybridbusiness model, combining the best practices of for-profit and not-for-profit entities. WomanCare Global has regulatoryand quality departments that assure adherence to regulatory requirements and global quality standards in addition to acomprehensive global sales, marketing, and distribution channel. For more information about WomanCare Global, visitwww.womancareglobal.com

Contact

Ellen Thomas
Corporate Communications
+1.919.442.2619

Matthew Reeves, MD, MPH Joins WomanCare Global Team

WomanCare Global Acquires Two New Oral Contraceptives

Posted on November 4, 2010

WomanCare Global is pleased to announce an expansion of their global product portfolio to include Roselle®, a combined oral contraceptive (COC) pill containing 150 micrograms of levonorgestrel and 30 micrograms of ethinylestradiol and Optinor®, a progesterone-only emergency contraception pill (ECP) containing 750 micrograms of levonorgestrel.

Both products were developed by ICON in partnership with a trusted generic manufacturer following an extensive in-depth qualityand technical assessment process undertaken by qualified experts in 2005. Both formulations are included in the WHO InteragencyList of Essential Medicines for Reproductive Health. ICON is the International Planned Parenthood Federation (IPPF) subsidiaryresponsible for commodity supply to IPPF member associations.

With this acquisition, WomanCare Global has global rights to Roselle® and Optinor® and a partner in making these branded products available to IPPF’s global network of Member Associations located in over 170 countries. WomanCare Global will also market these products to other public and private sector markets around the world using their established global supply chain and logistics network.

“This partnership with WomanCare Global is a significant step forward in expanding access to quality assured generic hormonalcontraceptives at competitive prices” said ICON’s General Manager, David Smith.

“WomanCare Global is excited about this important strategic alliance with a key partner” said WCG Chief Operating Officer SaundraPelletier. “The addition of these 2 new products to our global portfolio will make a significant difference to women around the worldwho deserve access to high-quality and affordable products. Roselle® and Optinor® will become important options for women.”

About WomanCare Global

WomanCare Global provides access to high-quality, innovative and affordable reproductive healthcare technologies forcontraception, fertility and pregnancy management. WomanCare Global’s mission is to expand the availability of these technologiesin both public and private sectors via an established global supply chain reaching over 80 countries and growing, with particularfocus on under-served markets in Africa, Asia and Latin America. WomanCare Global is a hybrid business model, combining the bestpractices of for-profit and not-for-profit entities. WomanCare Global has regulatory and quality departments that assure adherenceto regulatory requirements and global quality standards in addition to a comprehensive global sales, marketing, and distributionchannel. For more information about WomanCare Global, visit www.womancareglobal.com

Contact

Ellen Thomas
Corporate Communications
+1.919.442.2619

WomanCare Global Acquires Two New Oral Contraceptives

WomanCare Global Advertises in Times Square

Posted on December 15, 2010

CHAPEL HILL, N.C., — WomanCare Global is pleased to announce that it is running an advertisement on the famous CBS Super Screen in New York’s Times Square. The purpose of the advertisement is to call attention to the estimated 215 million women worldwide that do not have access to modern contraception.1

“Women are the cornerstone of every society around the world. When women are empowered, everyone benefits ? children, families and entire communities. Empowerment starts with women being able to control their own reproductive choices,” said WomanCare Global’s Chief Operating Officer, Saundra Pelletier. “The CBS Super Screen in Times Square is a world icon and a perfect place to call attention to the fact that women still do not have access to safe, affordable and high-quality reproductive choices. We hope our advertisement will bring these 215 million women to the forefront of viewer’s minds ? causing them to stop, take notice and take action. We at WomanCare Global firmly believe that every woman, no matter where she lives, and no matter who she is, should have easy access to reproductive choices.”

The CBS Super Screen is located on 42nd Street between 7th and 8th Avenues. WomanCare Global’sadvertisement will run once every hour from December 10, 2010 through January 10, 2011. It is anticipatedthat approximately 22.5 million people will pass through Times Square during this time period.

About WomanCare Global

WomanCare Global provides access to high-quality, innovative and affordable reproductive healthcaretechnologies for contraception, fertility and pregnancy management. WomanCare Global’s mission is toexpand the availability of these technologies in both public and private sectors via an established globalsupply chain reaching over 80 countries and growing, with particular focus on under-served markets in Africa,Asia and Latin America. WomanCare Global is a hybrid business model, combining the best practices of forprofitand not-for-profit entities. WomanCare Global has regulatory and quality departments that assureadherence to regulatory requirements and global quality standards in addition to a comprehensive global sales,marketing, and distribution channel. For more information about WomanCare Global, visitwww.womancareglobal.com

Contact

Ellen Thomas
WomanCare Global Corporate Communications
+1.919.442.2619

1. Susheela Singh et al., Adding It Up: The Costs and Benefits of Investing in Family Planning and Maternal and Newborn Health, New York: Guttmacher Institute and United Nations Population Fund, 2009.

WomanCare Global Advertises in Times Square

WCG to Distribute Mifepristone in Europe and Africa

Posted on February 8, 2012

LONDON, UK ― WomanCare Global announced today that mifepristone has been added to their reproductive healthcare portfolio. Through an agreement with Linepharma, WomanCare Global will provide sales, marketing,
provider training and distribution of mifepristone in seven European and seven African countries.

Linepharma’s mifepristone is labeled for use as a single 200mg tablet of mifepristone to perform medical abortion in conjunction with a prostaglandin, in compliance with the World Health Organization’s recommendation. Linepharma’s mifepristone is manufactured in Europe and is currently approved in five E.U. countries.

The planned distribution of mifepristone by WomanCare Global in 14 countries will ensure that close to 55 million women will have another safe, quality product to manage their reproductive health.

“To date, a European-approved mifepristone has only been available in a limited geographic area” said WomanCare Global CEO Saundra Pelletier. “Providing access to quality reproductive health supplies ensures that women can choose if and when to have children. This is a critical factor in helping women live to their fullest potential.”

“Teaming with WomanCare Global is an achievement for Linepharma which has been built with the aim to bring products approved by the most demanding regulatory agencies and to provide not-for-profit organizations with pharmaceutical support in order to allow women in developing countries to get access to high-quality medicines” said Linepharma General Manager Thomas Kozminski.

“In our many years of working in women’s reproductive health, we are very aware of the unmet need for higher quality products. We are so pleased that WomanCare Global is able to provide a solution and make an EU-manufactured mifepristone available to the women we serve” said Ipas CEO Liz Maguire. “Ipas will work very closely with WomanCare Global on expanding access to mifepristone in Africa. Bringing this life saving technology to women in low-resource settings is critical to reducing deaths and injuries from unsafe abortion and helping women make their own reproductive decisions.”

About WomanCare Global

WomanCare Global is a nonprofit organization working with partners around the world to improve the lives of women by providing access to affordable, quality reproductive health products. The organization believes that
every woman, no matter where she lives, should have control over her reproductive health and family planning needs, ultimately improving her ability to care for herself and her family. WomanCare Global closes the access gap by bringing the same quality products available in the developed world to developing countries. WomanCare Global serves both public and private sectors via an established global supply chain reaching countries around the world, with particular focus on under-served markets in Africa, Asia and Latin America. WomanCare Global was established by Ipas in 2009 and the two organizations continue to work closely together. WomanCare Global
operates independently as a UK Registered Charity (N°1138896). For more information, please visit womancareglobal.org

Contact

Ellen Thomas
[email protected]

About Linepharma

Linepharma is a European pharmaceutical company which identifies, develops and registers medicines or medical devices which offer health benefits to women and need specific approaches for commercialization. Currently, the company is focused to make medical abortion safe and affordable and to develop medicines for the treatment and prevention of ob/gyn conditions such as post-partum haemorrhage. Linepharma contributes to training services related to the use of its medicines in developed and developing countries.

Contact

Marion Ulmann
[email protected]

WCG to Distribute Mifepristone in Europe and Africa

WomanCare Global Completes Relocation of U.S. Headquarters

Posted on April 4, 2012

SAN DIEGO, CA – WomanCare Global confirmed today that the relocation of its United States headquarters to San Diego, California has been completed. Originally headquartered in Chapel Hill, N.C., the organization decided to relocate to the San Diego market to be closer to potential partners and to gain access to new and emerging markets including Latin America and Asia.

Saundra Pelletier, WomanCare Global CEO, said, “We are thrilled with the number of interested and engaged stakeholders in the San Diego market and we look forward to partnering with individuals and organizations that understand our mission and fundamentally recognize that empowered women are the cornerstone of every productive society.”

She continued, “Many of our global philanthropic concerns are joined with, or stem from, women lacking uninterrupted access to safe, high-quality and affordable reproductive healthcare products. It is our commitment at WomanCare Global to create and sustain access opportunities and to ensure that a portfolio of choice is available to every woman so she can have control over her own fertility.”

WomanCare Global has a comprehensive product portfolio focused on women’s reproductive health. Their products cover a wide array of reproductive healthcare needs including contraception, pregnancy management and fertility.

About WomanCare Global:

WomanCare Global is a nonprofit organization working with partners around the world to improve the lives of women by providing access to affordable, quality reproductive health products. The organization believes that every woman, no matter where she lives, should have control over her reproductive health and family planning needs, ultimately improving her ability to care for herself and her family. WomanCare Global closes the access gap by bringing the same quality products available in the developed world to developing countries. WomanCare Global serves both public and private sectors via an established
global supply chain reaching more than 100 countries around the world, with particular focus on under-served markets in Africa, Asia and Latin America. WomanCare Global was established by Ipas in 2009 and the two organizations continue to work closely together. WomanCare Global operates independently as a UK Registered Charity (N°1138896). For more information, please visit womancareglobal.org

Media contact:

Marla Cimini
Gemini Healthcare
+1 856 616 1194
[email protected]

WomanCare Global Completes Relocation of U.S. Headquarters